Company: EVGN
Filing Date: 2025-03-28
Form Type: POS AM
Source: 0001178913-25-001096
Chunk: 3

Company: Evogene Ltd.
Filing Date: 2025-03-28
Form: POS AM
Chunk 3
---
 described under the heading “Item 3 Key Information - D. Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2024, which we filed with the Securities and Exchange Commission on March 27, 2025, and in other documents incorporated by reference into this prospectus . Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The date of this prospectus is _________, 2025 TABLE OF CONTENTS Page

| ABOUT THIS PROSPECTUS                                |  1 |
| PROSPECTUS SUMMARY                                   |  2 |
| THE OFFERING                                         |  3 |
| RISK FACTORS                                         |  4 |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS |  7 |
| USE OF PROCEEDS                                      |  8 |
| CAPITALIZATION                                       |  8 |
| SELLING SHAREHOLDER                                  |  9 |
| PLAN OF DISTRIBUTION                                 | 11 |
| DESCRIPTION OF SHARE CAPITAL                         | 12 |
| EXPENSES                                             | 16 |
| LEGAL MATTERS                                        | 16 |
| EXPERTS                                              | 16 |
| WHERE YOU CAN FIND ADDITIONAL INFORMATION            | 16 |
| INFORMATION INCORPORATED BY REFERENCE                | 17 |
| ENFORCEABILITY OF CIVIL LIABILITIES                  | 18 |

ABOUT THIS PROSPECTUS As permitted under the rules of the U.S. Securities and Exchange Commission, or the SEC, this prospectus incorporates important information about us that is contained in documents that we have previously filed with the SEC but that are not included in or delivered with this prospectus. You may obtain copies of these documents, without charge, from the website maintained by the SEC at www.sec.gov, as well as other sources. You may also obtain copies of the incorporated documents, without charge, upon written or oral request to Evogene Ltd., 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel, Attention: VP Legal Affairs & Company Secretary. The telephone number of our registered office is Telephone: +972-8-931-1900. See “Where You Can Find Additional Information.” You should rely only on information contained in and incorporated by reference into this prospectus. We have not, and the